Vyne stock plunged after repibresib failed key endpoints in a Phase 2b vitiligo trial. BTIG and HC Wainwright downgraded the stock, citing limited clarity. Despite this, retail traders stayed ‘extremely bullish’ amid an 11,800% surge in message volume, noting Vyne’s $39 million cash and potential from its InhiBET platform or activist interest.